ASX:ACLHealthcare
Australian Clinical Labs H1 2026 Margin Compression Challenges Bullish Efficiency Narratives
Australian Clinical Labs (ASX:ACL) has just posted its H1 2026 numbers, with revenue of A$365.4 million and net income of A$5.6 million translating to basic EPS of A$0.03, setting a measured tone for the half. The company has seen revenue sit in a tight band over the last year, moving from A$369.2 million in H1 2025 to A$372.1 million in H2 2025 and now A$365.4 million, while EPS has changed from A$0.06 in H1 2025 to A$0.12 in H2 2025 and A$0.03 in the latest half, leaving investors focused...